Fennec Pharmaceuticals, Inc.
$215.0K 1,115 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
LEO Pharma AS
LEO Pharma AS reported $214,704.12 across General Payments, Research, and Ownership to 200 physicians and teaching hospitals across 258 transactions.
- $214.7K
- All-tracks total
- 258
- Transactions
- 200
- Recipients
- −$48.9K
- General Payments vs PY2023
LEO Pharma AS reported $214,704.12 across all CMS Open Payments tracks (General + Research + Ownership) to 200 physicians and teaching hospitals in Program Year 2024 - ranking #980 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $192,034.12, averaging $1.1K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer leo-pharma-as LEO Pharma AS
$214.7K · #980/1,925 · 0.0% industry · PY2024
- TOT $214.7K
- RANK #980
- SHARE 0.0%
- TXN 258
- RCP 200
- CAT 4
- GEN $192.0K
- ΔGEN −$48.9K
- TOP1 12.9%
- PY 2024
Volume peers
Nearest volume peer: Fennec Pharmaceuticals, Inc. ($215.0K)
LEO Pharma AS sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
LEO Pharma AS's CMS-reported General Payments decreased by $48.9K (−20.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: LEO PHARMA ASPY2023: LEO PHARMA ASPY2024: LEO Pharma AS. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $240,979.91
- PY2024
- $192,034.12
What the Data Shows for LEO Pharma AS
$214,704.12: that is what LEO Pharma AS reported in payments to 200 physicians and teaching hospitals during Program Year 2024, spread across 258 transactions ($832.19 per transaction, $1.1K per recipient). The company sits at rank #980 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
"Consulting Fee" leads the 4-category general-payment breakdown below at $149.9K (78.1% of General Payments, 43 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 4 types of general payments, LEO Pharma AS's largest category was "Consulting Fee" at $149.9K - 78.1% of General Payments.
LEO Pharma AS reports 4 general-payment categories - the top three are Consulting Fee (78.1%), Compensation for Services Other Than Consulting (19.0%), and Travel and Lodging (2.7%). The remaining 1 category make up 0.3% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How LEO Pharma AS divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $149.9K | 43 | 78.1% |
| Compensation for Services Other Than Consulting | $36.5K | 18 | 19.0% |
| Travel and Lodging | $5.1K | 84 | 2.7% |
| Food and Beverage | $523.29 | 55 | 0.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $106,056.70 (55.2%) of $192,034.12 in this company's General Payments records across 25 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for LEO Pharma AS
The five named recipients with the highest reported General Payments from this company
- 1
Jonathan Silverberg
$24,706.40 across 21 reported transactions
- 2
David Cohen
$22,656.62 across 33 reported transactions
- 3
Raj Chovatiya
$21,665.69 across 36 reported transactions
- 4
Firas Hougeir
$20,755.44 across 4 reported transactions
- 5
April Armstrong
$16,272.55 across 4 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as LEO Pharma AS's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about LEO Pharma AS.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with LEO Pharma AS.
Showing 6 of 1,924 companies with CMS-reported payment data.
Planmeca USA, Inc.
$214.2K 226 recipients
Compare payment profiles
PureLife, LLC
$214.1K 2,242 recipients
Compare payment profiles
Acarix USA Inc.
$215.3K 83 recipients
Compare payment profiles
Mohawk Hospital Equipment, Inc.
$212.0K 4 recipients
Compare payment profiles
Surgical Specialties Corporation (us), Inc. (dba Corza Medical)
$210.1K 577 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.